细胞因子在慢性髓系白血病中的研究进展  

Progress of study on cytokines in chronic myeloid leukemia-review

作　　者：张丹阳[1] 张永清[1] 

机构地区：[1]解放军第309医院血液科,北京100091

出　　处：《现代肿瘤医学》2016年第17期2820-2823,共4页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81400075)

摘　　要：慢性髓系白血病(chronic myeloid leukemia CML)是一类起源于造血干细胞的恶性克隆性疾病,酪氨酸激酶抑制剂(TKI)对CML慢性期有很好的治疗效果,但治疗过程中会出现耐药、发生急变。CML急变和TKI的耐药是目前影响该病治疗和预后的主要障碍。近年来研究发现细胞因子网络紊乱及其活动与CML是相关的,造血微环境中许多造血和趋化相关的细胞因子在CML中异常表达。细胞因子在CML的进展和耐药中起到重要作用。本文将对细胞因子在CML进展机制中的作用,细胞因子与临床耐药的相关性及当前针对细胞因子的新的治疗方法等方面作一综述。Chronic myeloid leukemia（ CML） is a kind of clone disease that originated in hematopoietic stem cells.Tyrosine kinase inhibitor（ TKI） has been used as first-line agents for the treatment of chronic myeloid leukemia,and has good therapeutic effect for CML chronic phase,but the prognosis of some CML BP patients and patients with TKI resistance is poor.Abnormal expression and activities of a number of cytokines are associated with CML,in which immune dysregulation is pronounced as evidenced by the dysregulation of several chemokine and hematopoietic growth factors genes.It is becoming increasingly clear that the dysregulation of cytokine levels contributes to the progression and drug resistant of CML.In this review,the role of cytokines in the progression of CML,the drug resistant of cytokines with CML,current therapies and the combination with the new treatments targeting cytokines are summarized.

关 键 词：细胞因子 慢性粒细胞白血病 BCR-ABL融合基因 

分 类 号：R733.72[医药卫生—肿瘤]